A systematic review of the time course of atherosclerotic plaque regression

Atherosclerosis

Volumn 234, Issue 1, 2014, Pages 75-84

  Noyes, Adam M ^a   Thompson, Paul D ^b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Atherosclerosis; Regression; Statins

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; HEART INFARCTION; HUMAN; MEDLINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUDDEN DEATH; SYSTEMATIC REVIEW; THORACIC AORTA; TIME TO TREATMENT; TREATMENT WITHDRAWAL; PLAQUE, ATHEROSCLEROTIC; REMISSION; TIME;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PLAQUE, ATHEROSCLEROTIC; REMISSION INDUCTION; TIME FACTORS;

EID: 84897948804     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.02.007     Document Type: Review

References (65)

1. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis: characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983, 50:127-134.
2. Frink R.J. Chronic ulcerated plaques: new insights into the pathogenesis of acute coronary disease. JInvasive Cardiol 1994, 6:173-185.
3. Falk E. Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am J Cardiol 1989, 63(Suppl.E):114E-120E.
4. Falk E., Shah P.K., Fuster V. Coronary plaque disruption. Circulation 1995, 92:657-671.
5. Crisby M., Nordin-Fredriksson G., Shah P.K., et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001, 103:926-933.
6. Hibi K., Kimura T., Kimura K., et al. JAPAN-ACS Investigators. Atherosclerosis 2011, 219:743-749.
7. Brown B.G., Zhao X.Q. Lipid-lowering therapy. Clinical trials in cardiovascular disease (A companion to Braunwald's heart disease) 1999, 199-216. WB Saunders, Philadelphia, PA. C.H. Hennekens (Ed.).
8. Kamal-Bahl S.J., Burke T., Watson D., Wentworth C. Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 2007, 99:530-534.
9. Cohen J.D., Brinton E.A., Ito M.K., Jacobson T.A. Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users. JClin Lipidol 2012, 6:208-215.
10. Corti R., Fayad Z.A., Fuster V., et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 2001, 104:249-252.
11. Corti R., Fuster V., Fayad Z.A., et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. JAm Coll Cardiol 2005, 46:106-112.
12. Terry J.G., Carr J.J., Kouba E.O., et al. Effect of simvastatin (80 mg) on coronary and abdominal aortic arterial calcium (from the coronary artery calcification treatment with zocor [CATZ] study). Am J Cardiol 2007, 99:1714-1717.
13. Budoff M.J., Lane K.L., Bakhsheshi H., et al. Rates of progression of coronary calcium by electron beam tomography. Am J Cardiol 2000, 86:8-11.
14. Hecht H.S., Harman S.M. Relation of aggressiveness of lipid-lowering treatment to changes in calcified plaque burden by electron beam tomography. Am J Cardiol 2003, 92:334-336.
15. Howard B.V., Roman M.J., Devereux R.B., et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 2008, 299:1678-1689.
16. Suzuki T., Nozawa T., Fujii N. Plaque regression in one artery is not necessarily associated with parallel changes in other vascular beds. Heart Vessels 2011, 26:242-251.
17. Toi T., Taguchi I., Yoneda S., et al. Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin. Circ J 2009, 73:1466-1472.
18. Salonen R., Nyyssonen K., Porkkala E., et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995, 92:1758-1764.
19. Takahashi T., Ishii N., Itai K., Goto R., Higashi K., Kobori S. HMG-CoA reductase inhibitors suppress the development and progression of carotid artery intimal medial thickening in hypercholesterolemic type 2 diabetic patients. JAtheroscler Thromb 2005, 12:149-153.
20. Yu C.M., Zhang Q., Lam L., et al. Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart 2007, 93:933-939.
21. Callister T.Q., Raggi P., Cooil B., Lippolis N.J., Russo D.J. Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography. NEngl J Med 1998, 339:1972-1978.
22. Achenbach S., Ropers D., Pohle K., et al. Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation. Circulation 2002, 106:1077-1082.
23. Furberg C.D., Adams H.P., Applegate W.B., et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994, 90:1679-1687. for the Asymptomatic Carotid Artery Progression Study (ACAPS) research group.
24. Mercuri M., Bond M.G., Sirtori C.R., et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study (CAIUS). Am J Med 1996, 101:627-634.
25. de Groot E., Zwinderman A.H., van der Steen A.F., et al. Interuniversity Cardiology Institute of The Netherlands, Utrecht, The Netherlands. Regression growth evaluation statin study. Ultrasound Med Biol 1998, 24:825-832. Variance components analysis of carotid and femoral intima-media thickness measurements. REGRESS Study Group.
26. MacMahon S., Sharpe N., Gamble G., et al. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation 1998, 97:1784-1790.
27. Smilde T.J., van W.S., Wollersheim H., et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001, 357:577-581.
28. Taylor A.J., Kent S.M., Flaherty P.J., et al. ARBITER: arterial biology for the investigation of the treatment effects of reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima-medial thickness. Circulation 2002, 106:2055-2060.
29. de Sauvage Nolting, de Groot E., Zwinderman A.H., Buirma R.J., Trip M.D., Kastelein J.J. Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin. Arch Intern Med 2003, 163:1837-1841.
30. Crouse J.R., Raichlen J.S., Riley W.A., et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007, 297:1344-1353.
31. Crouse J.R., Byington R.P., Bond M.G. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995, 75:455-459.
32. Beishuizen E.D., van de Ree M.A., Jukema J.W., et al. Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease. Diabetes Care 2004, 12:2887-2892.
33. Bots M.L., Visseren F.L., Evans G.W., et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007, 370:153-160.
34. Kastelein J.J., van Leuven S.I., Burgess L., et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. NEngl J Med 2007, 356:1620-1630.
35. Kastelein J.J., Akdim F., Stroes E.S., et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. NEngl J Med 2008, 358:1431-1443.
36. Underhill H.R., Yuan C., Zhao X.Q., et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J 2008, 155:584.e1-584.e8.
37. Yamada T., Azuma A., Sasaki S., Sawada T., Matsubara H. Randomized evaluation of atorvastatin in patients with coronary heart disease: a serial intravascular ultrasound study. Circ J 2007, 71:1845-1850.
38. Hong M.K., Lee C.W., Kim Y.H., et al. Usefulness of follow-up low-density lipoprotein cholesterol level as an independent predictor of changes of coronary atherosclerotic plaque size as determined by intravascular ultrasound analysis after statin (atorvastatin or simvastatin) therapy. Am J Cardiol 2006, 98:866-870.
39. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071-1080.
40. Okazaki S., Yokoyama T., Miyauchi K., et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation 2004, 110:1061-1068.
41. Jensen L.O., Thayssen P., Pedersen K.E., Stender S., Haghfelt T. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation 2004, 110:265-270.
42. Tani S., Watanabe I., Anazawa T., et al. Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound. Am J Cardiol 2005, 96:1089-1094.
43. Yokoyama M., Komiyama N., Courtney B.K., et al. Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study. Am Heart J 2005, 150:287.
44. Petronio A.S., Amoroso G., Limbruno U., et al. Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: a randomized study with intravascular ultrasound. Am Heart J 2005, 149:520-526.
45. Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA 2006, 295:1556-1565. for the ASTEROID Investigators.
46. Hiro T., Kimura T., Morimoto T., et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). JAm Coll Cardiol 2009, 12:293-302.
47. Hong Y.J., Jeong M.H., Hachinohe D., et al. Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis. Circ J 2011, 75:398-406.
48. Schartl M., Bocksch W., Koschyk D.H., et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 2001, 104:387-392.
49. Kawasaki M., Sano K., Okubo M., et al. Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound. JAm Coll Cardiol 2005, 45:1946-1953.
50. Blankenhorn D.H., Azen S.P., Kramsch M., et al. Coronary angiographic changes with lovastatin therapy: the monitored atherosclerosis regression study (MARS). Ann Intern Med 1993, 119:969-976.
51. Jukema J.W., Bruschke A.V., van Boven A.J., et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995, 91:2528-2540.
52. Teo K.K., Burton J.R., Buller C.E., et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis. The Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000, 102:1748-1754.
53. Hecht H.S., Harman S.M. Comparison of the effects of atorvastatin versus simvastatin on subclinical atherosclerosis in primary prevention as determined by electronbeam tomography. Am J Cardiol 2003, 91:42-45.
54. Schmermund A., Achenbach S., Budde T., et al. Effect of intensive versus standard lipidlowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial. Circulation 2006, 113:427-437.
55. Houslay E.S., Cowell S.J., Prescott R.J., et al. Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial. Heart 2006, 92:1207-1212.
56. Yonemura A., Momiyama Y., Fayad Z.A., et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. JAm Coll Cardiol 2005, 45:733-742.
57. Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007, 115:459-467.
58. Nicholls S.J., Tuzcu E.M., Sipahi I., et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007, 297:499-508.
59. Nicholls S.J., Ballantyne C.M., Barter P.J., et al. Effect of two intensive statin regimens on progression of coronary disease. NEngl J Med 2011, 365:2078-2087.
60. Raggi P., Davidson M., Callister T.Q., et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: beyond endorsed lipid lowering with EBT scanning (BELLES). Circulation 2005, 112:563-571.
61. Johnsen S.H., Mathiesen E.B., Joakimsen O., et al. Carotid atherosclerosis is a stronger predictor of myocardial infarction in women than in men: a 6-yearfollow-up study of 6226 persons: the Tromsø Study. Stroke 2007, 38:2873-2880.
62. Inaba Y., Chen J.A., Bergmann S.R. Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: a meta-analysis. Atherosclerosis 2012, 220:128-133.
63. Thompson P.D., Balady G.J., Chaitman B.R., Clark L.T., Levine B.D., Myerburg R.J. 36th Bethesda conference eligibility recommendations for competitive athletes with cardiovascular abnormalities. Task force 6: coronary artery disease. JAm Coll Cardiol 2005, 45:1348-1353.
64. Noguchi T., Yamada N., Higashi M., Goto Y., Naito H. High-intensity signals in carotid plaques on T1-weighted magnetic resonance imaging predict coronary events in patients with coronary artery disease. JAm Coll Cardiol 2011, 58:423-425.
65. Albano A.J., Thompson P.D., Kapur N.K. Acute coronary thrombosis in Boston marathon runners. NEngl J Med 2012, 366:184-185.